AVANOS MEDICAL, INC.

Listed Company

AVNSCIK 0001606498NYSELarge AcceleratedOrthopedic, Prosthetic & Surgical Appliances & SuppliesDelawareFY ends Dec 31

Period

FY 2025

Revenue

$701.20M

Net Income

$-72.90M

Total Assets

$1.07B

Equity

$778.20M

Shares Out

46.82M

Op. Cash Flow

$74.70M

AVNS$24.98+114.05% · past yearDBEQ Basic

Daily closing prices

Business

Avanos Medical is a medical technology company that develops, manufactures and markets medical device solutions across two segments: Specialty Nutrition Systems and Pain Management and Recovery. The company offers enteral feeding tubes (MIC-KEY, Corpak), neonatal solutions (NeoMed), surgical pain pumps (ON-Q, ambIT), cold-compression therapy (Game Ready), and radiofrequency ablation pain therapies (COOLIEF, Trident, ESENTEC). Products are sold globally to hospitals, ambulatory care centers and other healthcare providers through direct sales and third-party distributors, with manufacturing facilities in the United States, Mexico and Canada.

Summary from 10-K filed 2026-02-24

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net Sales	701	688	673	684	587
Cost of products sold	347	307	294	290	288
Gross Profit	354	381	380	394	299
Research and development	23	26	27	29	31
Selling and general expenses	316	319	335	327	285
Goodwill and intangibles impairment	77	437	0	0	—
Other (income) expense, net	−400,000	−4	13	3	22
Operating (Loss) Income	−62	−396	4	36	−39
Interest income	3	5	3	1	200,000
Interest expense	−8	−12	−15	−10	—
Loss Before Income Taxes	−66	−403	−8	27	−42
Income tax (provision) benefit	−7	17	−2	−5	11
Loss from Continuing Operations	−73	−386	−10	22	−31
Loss from discontinued operations, net of tax	0	−6	−52	29	37
Net Loss	−73	−392	−62	51	6
Continuing operations (in dollars per share)	−1.57	−8.4	−0.21	0.46	−0.64
Discontinued operations (in dollars per share)	0	−0.13	−1.11	0.62	0.77
Basic Loss Per Share (in dollars per share)	−1.57	−8.53	−1.32	1.08	0.13
Continuing operations (in dollars per share)	−1.57	−8.4	−0.21	0.46	−0.64
Discontinued operations (in dollars per share)	0	−0.13	−1.11	0.61	0.77
Diluted Loss Per Share (in dollars per share)	−1.57	−8.53	−1.32	1.07	0.13

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	90	108	88	128	119
Accounts receivable, net of allowances	104	133	143	168	131
Inventories	148	139	163	132	159
Prepaid and other current assets	14	14	29	14	19
Total Current Assets	355	393	487	624	428
Property, Plant and Equipment, net	113	111	117	119	168
Operating Lease Right-of-Use Assets	28	34	27	28	39
Goodwill	395	456	796	760	743
Other Intangible Assets, net	118	112	240	234	141
Deferred Tax Assets	33	25	7	5	10
Other Assets	32	23	19	18	17
TOTAL ASSETS	1,074	1,154	1,692	1,787	1,604
Current portion of long-term debt	10	9	9	6	0
Current portion of operating lease liabilities	8	11	13	12	15
Trade accounts payable	56	54	56	68	56
Accrued expenses	91	91	93	98	68
Total Current Liabilities	165	166	235	191	139
Long-Term Debt	90	125	159	226	130
Operating Lease Liabilities	20	25	28	33	43
Deferred Tax Liabilities	6	6	24	25	12
Other Long-Term Liabilities	14	4	10	21	9
Total Liabilities	296	326	456	496	333
Commitments and Contingencies	—	—	—	—	—
Preferred stock - $0.01 par value - authorized 20,000,000 shares, none issued	0	0	0	0	0
Common stock - $0.01 par value - authorized 300,000,000 shares, 46,456,462 outstanding at December 31, 2025 and 45,962,627 outstanding at December 31, 2024	500,000	500,000	500,000	500,000	500,000
Additional paid-in capital	1,692	1,679	1,664	1,646	1,629
Accumulated deficit	−780	−707	−315	−253	−304
Treasury stock	−102	−99	−86	−67	−21
Accumulated other comprehensive loss	−32	−45	−27	−36	−34
Total Stockholders Equity	778	829	1,236	1,291	1,271
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	1,074	1,154	1,692	1,787	1,604

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	39	46	46	48	38
Stock-based compensation	13	14	16	16	13
Loss on RH disposal	0	0	71	0	0
Net losses on asset dispositions and asset impairments	9	1	2	1	—
Accounts receivable	31	−7	39	−25	−11
Inventories, net of allowance	200,000	39	5	−31	16
Prepaid expenses and other assets	1	15	−20	3	−2
Accounts payable	600,000	−900,000	−14	35	−12
Accrued expenses	−13	−11	−28	−7	33
Deferred income taxes and other	−10	−39	−22	0	—
Cash Provided by Operating Activities	75	101	32	91	87
Capital expenditures	−32	−18	−18	−19	−21
Proceeds from the sale of assets	4	0	0	—	—
Proceeds from the RH divestiture	0	0	89	0	0
Proceeds from RH divestiture post-closing settlement	0	2	0	0	—
Acquisition of assets and businesses, net of cash acquired	−28	0	−50	−116	0
Investments in non-affiliates	−5	−12	0	0	—
Cash (Used in) Provided by Investing Activities	−61	−28	22	−135	−21
Secured debt repayments	−9	−9	−5	−127	—
Revolving credit facility proceeds	0	20	55	150	20
Revolving credit facility repayments	−25	−45	−115	−170	0
Purchase of treasury stock	−3	−13	−19	−46	−12
Proceeds from the exercise of stock options	700,000	1	1	2	—
Payment of contingent consideration liabilities	0	−4	−12	0	0
Cash Used in Financing Activities	−37	−49	−94	57	−55
Effect of Exchange Rate Changes on Cash and Cash Equivalents	5	−4	200,000	−3	−4
(Decrease) Increase in Cash and Cash Equivalents	−18	20	−40	9	7
Cash paid for income taxes	14	3	24	−3	−45
Cash paid for interest	7	12	15	8	3
Capital expenditures included in accounts payable or accrued expenses	2	6	3	4	6

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is AVANOS MEDICAL, INC.'s CIK number?

AVANOS MEDICAL, INC.'s SEC CIK number is 0001606498 (1606498). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find AVANOS MEDICAL, INC.'s SEC filings?

All of AVANOS MEDICAL, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did AVANOS MEDICAL, INC. last report earnings?

AVANOS MEDICAL, INC. (AVNS) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001606498-26-000061). This is AVANOS MEDICAL, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is AVANOS MEDICAL, INC.'s most recent earnings 8-K?

AVANOS MEDICAL, INC.'s latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0001606498-26-000061. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View AVANOS MEDICAL, INC.'s latest earnings 8-K →
Look up any company's CIK number →